TP53 and non-Hodgkin lymphoma: Across the spectrum of hematologic malignancies, Malignant lymphoma, large B-cell, diffuse and non-Hodgkin lymphoma, NOS exhibited relatively high TP53 mutation rates, reinforcing the prognostic significance of TP53 alterations in aggressive lymphoid malignancies.